Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Kevin Chen

Hand Surgery Chicago, IL Medical Doctor

NPI 1982862918 CMS profile 676531

2923 N California Ave, Suite 300, Chicago, IL 60618

Open in the dashboard

General payments

$5,899

86 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Kevin Chen of Chicago, IL is reported in the CMS Open Payments database as having received $5,899 across 86 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Hand Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $38 2
2024 General $157 2
2023 General $159 3
2022 General $1,904 4
2021 General $2,916 26
2020 General $274 25
2019 General $452 24

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kevin Chen
  • Hand Surgery median
  • Middle half of Hand Surgery
  • National median

In program year 2025, general payments to Kevin Chen were reported at $38. Among 1,842 Hand Surgery profiles paid that year, the median was $270 and the middle half received between $102 and $1,118.

Show as a table
Year Kevin Chen Hand Surgery median Middle half National median
2019 $452 $383 $106–$1,905 $163
2020 $274 $172 $51–$1,268 $114
2021 $2,916 $263 $71–$1,591 $132
2022 $1,904 $336 $87–$1,938 $149
2023 $159 $233 $81–$1,114 $160
2024 $157 $258 $88–$1,203 $164
2025 $38 $270 $102–$1,118 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medwest Associates $2,413 3 payments
  2. Exactech, Inc. $1,760 3 payments
  3. Horizon Therapeutics plc $611 57 payments
  4. Stryker Corporation $192 5 payments
  5. Acumed LLC $150 1 payment
  6. Abbott Laboratories $144 1 payment
  7. Arthrex, Inc. $140 1 payment
  8. Smith+Nephew, Inc. $138 1 payment
  9. Bioventus LLC $72 2 payments
  10. DePuy Synthes Sales Inc. $59 2 payments
  11. Other $220 10 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,520 82 payments
  2. Education $2,400 2 payments
  3. Travel and Lodging $978 2 payments
Products named General payments · program years 2019–2025
  1. Equinoxe $1,760 3 payments
  2. PENNSAID $556 52 payments
  3. GAMMA $153 3 payments
  4. Acu-Loc Wrist Plating System $150 1 payment
  5. Elbow Plating System $150 1 payment
  6. Anatomic Radial Head System $150 1 payment
  7. PERCLOSE PROGLIDE $144 1 payment
  8. Bioinductive Implant with Arthroscopic Delivery System - Medium $138 1 payment
  9. CAP-FIX $138 1 payment
  10. LENS 4K $138 1 payment
  11. Other $783 36 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

31

Median for Orthopedic Surgery: 203

Drug cost

$176

Median for Orthopedic Surgery: $1,433

Branded share of claims

51.6%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 16 $136
Tramadol Hcl Generic 15 $40

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$74,645

Of which drugs: $2,185

Medicare patients

286

Average age 73

Services billed

1,490

169 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 64%
Arthritis 50%
Ischemic heart disease 26%
Diabetes 25%
Depression 24%
Chronic kidney disease 15%
Heart failure 14%
Osteoporosis 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 88 291 $1,472
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 35 59 $45

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

86 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hand Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record